BMC Musculoskeletal Disorders · 2020 · 10 citations · 15 references
Denosumab therapy contributed to tumour regression. Three-level TES may be an effective and feasible strategy for managing large recurrent GCTs of the spine after denosumab therapy.
15
Sant P. Chawla, Robert M. Henshaw, Leanne L. Seeger et al. · The Lancet Oncology · 2013 · 573 citations
Giant Cell Tumor of Bone: Risk Factors for Recurrence
Frank M. Klenke, Doris E. Wenger, Carrie Y. Inwards et al. · Clinical Orthopaedics and Related Research · 2010 · 370 citations